Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Exchange Rate Effect (2020 - 2025)

Historic Exchange Rate Effect for Cellebrite DI (CLBT) over the last 6 years, with Q4 2025 value amounting to $56000.0.

  • Cellebrite DI's Exchange Rate Effect rose 10389.43% to $56000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 million, marking a year-over-year increase of 30306.55%. This contributed to the annual value of $2.5 million for FY2025, which is 30306.55% up from last year.
  • As of Q4 2025, Cellebrite DI's Exchange Rate Effect stood at $56000.0, which was up 10389.43% from -$189000.0 recorded in Q3 2025.
  • Cellebrite DI's 5-year Exchange Rate Effect high stood at $2.8 million for Q4 2022, and its period low was -$2.4 million during Q2 2022.
  • Over the past 5 years, Cellebrite DI's median Exchange Rate Effect value was -$21000.0 (recorded in 2023), while the average stood at -$28200.0.
  • As far as peak fluctuations go, Cellebrite DI's Exchange Rate Effect plummeted by 204320.0% in 2022, and later skyrocketed by 369591.84% in 2025.
  • Over the past 5 years, Cellebrite DI's Exchange Rate Effect (Quarter) stood at -$81000.0 in 2021, then surged by 3550.62% to $2.8 million in 2022, then tumbled by 66.65% to $932000.0 in 2023, then crashed by 254.29% to -$1.4 million in 2024, then surged by 103.89% to $56000.0 in 2025.
  • Its Exchange Rate Effect was $56000.0 in Q4 2025, compared to -$189000.0 in Q3 2025 and $1.8 million in Q2 2025.